Ginseng (the root of Panax ginseng C.A. MEYER, Araliaceae) is frequently taken orally, as a crude substance, as a traditional medicine in Asian countries. The major components of ginseng are ginsenosides, which contain an aglycone with a dammarane skeleton.
Inhibitory Effect of Ginsenoside Rb1 and Compound K on NO and Prostaglandin E2 Biosyntheses of RAW264.7 Cells Induced by Lipopolysaccharide
was centrifuged at 10000ϫg for 30 min, then washed twice with TS broth. The resulting precipitate was suspended in 100 ml water containing 1% ginsenoside Rb1, and incubated for 24 h at 37°C, then extracted with BuOH. This BuOH fraction was chromatographed on a silica gel column using CHCl 3 -MeOH-H 2 O (10 : 3 : 1, lower layer) to isolate compound K (120 mg). The isolated compound K was recrystallized with EtOH. Its purity was assayed by HPLC (Hitachi HPLC system: column, Lichrosorb NH2 (25ϫ0. 
Animals
Male Sprague-Dawley (SD) rats were supplied from the Charles River Oriental Animal Breeding Center (Seoul, Korea). All animals were housed in wire cages at 20-22°C, at 50Ϯ10% humidity, fed standard laboratory chow (Charles River Oriental Animal Breeding Center), and allowed water ad libitum. All procedures relating to the animals and their care conformed to the International Guidelines for the Principles of Laboratory Animal Care (NIH publication no. 85-23, revised 1985) .
Nitric Oxide Analysis Nitric oxide was determined by measuring the amount of nitrite in the cell culture supernatant, using Griess reagent, according to the manufacturer's protocol. The RAW 264.7 cells were stimulated with LPS (1 mg/ml) and test agents for 24 h, then briefly centrifuged. Next 150 ml of the cell culture supernatant was mixed with 150 ml of Griess reagent, followed by incubation for 10 min at room temperature (light protected). The absorbance was measured using an ELISA reader at 540 nm, and compared to a standard calibration curve prepared from sodium nitrite. 14) Assay of PGE2 The RAW 264.7 cells were seeded at 5ϫ10 4 cells per well in flat-bottomed 96-well plates. Test agents and LPS (1 mg/ml) were added to the culture medium, and incubated at 37°C for 20 h. The medium was collected in a microcentrifuge tube and centrifuged at 2800ϫg for 10 min. The supernatant was decanted into a new microcentrifuge tube, and the amount of PGE2 determined using a PGE2 Enzyme-Immuno-Assay kit.
Measurement of NO Production in LPS-Induced RAW264.7 Cells The RAW 264.7 cells were stimulated with LPS (1 mg/ml) for 16 h, and the cells were washed twice with PBS. They were then incubated with test agents for 16 h. Cells were briefly centrifuged, then 150 ml of the supernatant mixed with 150 ml of Griess reagent and incubated for 10 min at room temperature (light protected). The absorbance was measured using an ELISA reader at 540 nm, and compared to a standard calibration curve prepared from sodium nitrite (Ishihara et al., 2000) .
Measurement of COX Enzyme Activity The COX activities of the purified enzymes were determined using a cyclooxygenase inhibitor screening assay kit. In brief, ovine cyclooxygenase-1 or cyclooxygenase-2 was preincubated with or without various concentrations of test agents in 0.1 M Tris-HCl (pH 8.0) containing 5 mM EDTA, 2 mM phenol and 1 mM heme at 37°C for 2 min. The reactions were initiated by adding arachidonic acid to a final concentration of 100 mM, and incubated at 37°C for 2 min. One-twentieth the volume of 1 M HCl was added to the reaction mixtures to stop enzyme catalysis, followed by one tenth the volume of saturated stannous chloride (50 mg/ml). The reaction mixtures were incubated for 5 min at room temperature, and then the amount of prostaglandin E2 formed during the reaction was measured by an enzyme immunoassay.
Immunoblot Analysis of iNOS, COX-2 and NF-kB in LPS-Induced RAW264.7 Cells Immunoblot analyses of the iNOS, COX-2 and NF-kB were performed according to the method of Ishihara et al. 15) The RAW 264.7 cells were plated in 60 mm culture dishes (3ϫ10 6 cells), test agents and LPS (1 mg/ml) were added to the culture medium, and the cells were incubated at 37°C for 6 h (in NF-kB) or 20 h (in iNOS and COX-2). The cells were lysed on ice for 15 min in a hypotonic buffer containing 10 mM Tris (pH 8.0), 1.5 mM MgCl 2 , 1 mM DTT, 0.1% NP-40, 5 mg/ml pepstatin A and 5 mg/ml aprotinin, and centrifuged at 12000ϫg at 4°C for 15 min. Supernatant was used as the cytosol fraction for the immuoblot assays for the iNOS and COX-2 protein expressions. The pelleted nuclei fractions for the immunoblot assays of the NF-kB protein expression were resuspended in the extraction buffer, which contained 10 mM Tris (pH 8.0), 50 mM KCl, 300 mM NaCl, 1 mM DTT, 5 mg/ml pepstatin A and 5 mg/ml aprotinin. The mixture was then lysed on ice for 30 min. The lysed nuclei fraction was centrifuged at 12000ϫg at 4°C for 30 min. The resulting supernatant was used as a nuclei fraction for the analysis of NF-kB protein expression level. Protein expression levels of COX-2, iNOS, NF-kB and b-actin of the cell lysates (40 mg) were analyzed by the above immunoblot method.
Pharmacokinetics Study Ginsenoside Rb1 (50 mg/rat) was orally administered to three male SD rats (250-260 g), and urine was collected periodically at 3 h, 6 h, 12 and 24 h postdosing. The urine samples were treated according to the previously reported method. The urine (3 ml) was incubated at 37°C for 20 h with b-glucuronidase (10000 units, Sigma Co. MO, U.S.A.) in 1 ml of 1 M sodium acetate buffer (pH 4.5), and then applied on a preconditioned C 18 solidphase column (Sep-Pak, Waters Co., U.S.A.) preconditioned with 6 ml of 95% ethanol and 10 ml of distilled water. The column was washed with 4 ml of 10% methanol in distilled water and then eluted with 2 ml of methanol. The eluted sample was analyzed by HPLC [Hitachi System: column, m-Bondapak C 18 (3.9ϫ300 mm); elution solvent, methanol/water/ acetonitrile (20 : 30 : 50); elution rate, 1.0 ml/min; detecter, ELSD 800]. Ginsenoside Rg3 was used as an internal standard. The retention times of ginsenoside Rb1 and compound K were as follows: ginsenoside Rb1, 3.24 min; ginsenoside Rg3 (internal standard), 5.02 min; and compound K, 8.58 min.
Statistical Analysis All the data from the experiment were expressed as meanϮstandard deviation and the statistical significance was determined using Student's t-test.
RESULTS
To investigate the antiinflammatory effect of ginsenoside Rb1 and compound K on RAW264.7 cells, we examined whether ginsenoside Rb1 and compound K could modulate NO synthesis in LPS-stimulated cultures of the murine macrophages of the RAW 264.7 cells ( Table 1 ). The compound K significantly inhibited the production of NO in LPS-induced RAW 264.7 cells. Its IC 50 was 0.032 mM. To see the direct inhibition of the iNOS enzyme activity, NO production produced by the enzyme activity was measured with or without compound K in the cell-free system (Fig. 2) . When the RAW 264.7 cells were treated with LPS, NO level produced by the iNOS enzyme activity was significantly increased. The treatment of compound K at a concentration of more than 5 mM inhibited NO production. However, ginsenoside Rb1 did not inhibit the NO production in intact cell and cell-free systems.
Stimulation of the RAW 264.7 cells with LPS also increased the synthesis of PGE2, as shown in Table 1 . Compound K significantly suppressed the production of PGE2, with an IC 50 value of 0.004 mM. Therefore, the effect of compound K on the activities of COX-1 and COX-2 was investigated in a culture system (Fig. 3) . However, compound K did not inhibit the enzyme activities of either COX-1 or COX-2.
Whether ginsenoside Rb1 or compound K could affect the iNOS and COX-2 protein expressions was also examined. Stimulation of the RAW 264.7 cells with LPS resulted in accumulation of the iNOS protein, as determined by immunoblot analysis (Fig. 4) . Compound K reduced the levels of the iNOS protein in a dose-dependent manner. Densitometer scans of the respective blots showed that compound K at concentrations of 5 and 25 mM reduced the levels of the iNOS protein by 32 and 58%, respectively, compared with the control cells stimulated with LPS. However, the ginsenoside Rb1 did not inhibit COX-1 and 2 activities (data not shown). Stimulation of the RAW 264.7 cells with LPS also induced the expression of the COX-2 protein. Compound K at a concentration of 5 mM reduced the levels of the COX-2 protein by 64%, compared with the control cells stimulated with LPS. However, compound K at a concentration of 25 mM inhibited the level of COX-2 protein expression less than at the concentration of 5 mM. However, the inhibitory activity of the ginsenoside Rb1 on COX-2 protein expression was weak (12% inhibition) (data not shown). The effect of compound K on the activation of the nuclear transcription factor, NFkB, which induced both iNOS and COX-2, was also investigated. The NF-kB in the nuclei fraction was activated by LPS. However, compound K inhibited the activation of the NF-kB in LPS-stimulated RAW 264.7 cells. The amounts of NF-kB protein correlated with the reduced accumulation of the iNOS and COX-2 proteins. However, the inhibitory activity of the ginsenoside Rb1 was weak (7% inhibition).
DISCUSSION
The etiology of the allergy reactivity is based on the IgEmedicated pharmacological processes of a variety of cell populations, such as mast cells and basophils. 16) Degradation of mast cells and basophils with antigen-crosslinked IgE releases histamine, prostaglandins, leukotrienes and cytokines. These cytokines activate the chemotaxis and phagocytosis of neutrophils and macrophages. Finally, the cytokine-induced reaction causes tissue inflammation. 17) Many studies have demonstrated that some inducible enzyme (COX and iNOS)/cytokines and their reaction products are involved in chronic inflammatory disease. [18] [19] [20] COX-2, an inducible isoform of COX, is upregulated in inflammation. Inducible nitric oxide synthase (iNOS) is associated with inflammation, and its reaction product NO is involved in various diseases, such as psoriasis and atopic inflammation. Choo et al. reported that compound K inhibited potently passive cutaneous anaphylaxis reaction in mice, but ginsenoside Rb1 did not. 13) Therefore, to compare the biological activity of these ginsenosides and evaluate their antiinflammatory effect against allergic inflammation, we investigated the antiinflammatory activity of compound K in LPS-induced RAW264.7 cells. Compound K inhibited the production of NO and PGE2 in LPS-induced RAW 264.7 cells. Compound K inhibited NO production in a cell-free system. However, compound K did not inhibit the COX-1 and COX-2 enzyme activities. This result suggests that compound K may contribute to be the iNOS enzyme activity.
Compound K inhibited the expression of the iNOS and COX-2 proteins, although the reason compound K at a concentration of 25 mM induced COX-2 protein level could not be understood. Compound K also inhibited the activation of the NF-kB transcription factor, which regulates iNOS and COX-2 gene expressions on LPS-induced RAW264.7 cells. These results suggest that compound K can inhibit NO and PGE2 production by regulation of the signal transduction related to the activation of NF-kB.
In addition, we previously reported that compound K may be responsible for passive cutaneous anaphylaxis reaction inhibitory activities, such as atopic diseases, and that protopanaxadiol ginsenosides of ginseng were easily metabolized to compound K, when ginseng extract or ginsenoside was orally administered. [21] [22] [23] In the present study, compound K, but not ginsenoside Rb1, was detected in urine when ginsenoside Rb1 was orally administered to rats (Fig. 5) . However, the amount of compound K recovered in the urine was 0.3% of the orally administered ginsenoside Rb1. The residual ginsenoside was not only absorbed into the blood, but also slowly excreted in the urine. Based on these findings, ginsenoside Rb1 may be transformed to compound K, which can be effective for treating allergic inflammation. Ginsenoside Rb1 (50 mg per a rat) was orally administered into three male SD rats (250-260 g), and the urine sample was collected periodically at 3 h, 6 h, 12 and 24 h post-dosing.
